| Exelixis, Inc. Q1 2010 Earnings Call Transcript Exelixis, Inc. (EXEL)Q1 2010 Earnings Call TranscriptMay 11, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Axial Capital Again Adds to QLT Stake Market Folly submits:Just a few days ago we detailed how Eliav Assouline and Marc Andersen's hedge fund Axial Capital was buying shares of QLT Inc (QLTI). This trend continues as Axial recently filed another Form 4 with the SEC regarding QLTI shares. On July 6th, 2010, Axial purchased 109,157 shares of QLT Inc. at a price of $5.79 per share. This brings their total ownership up to 6,304,586 shares. Eliav and Andersen's hedge fund has been accumulating shares over the span of a few months now, continuing to buy as QLTI trades lower.The interesting thing with this play is that many have characterized QLT Inc as a value trap or a 'cigarette-butt' type of investment. It is essentially a play on the biotech company's royalty stream. Some argue that while the stream is healthy now, it is likely to decline. Assouline and Andersen seem to disagree as they continue to accumulate shares.Complete Story » seekingalpha.com |
Charles River's WuXi Acquisition Axed, Trius Fails to Debut: Biotech Deals That Didn’t Happen The Burrill Report submits: By Marie DaghlianThe biggest deals news of the week were the deals that didn’t happen. Charles River Laboratories (CRL) called off its $1.6 billion deal to buy WuXi PharmaTech (WX) due to investor opposition led by Jana Partners, its largest shareholder (see story). And, two life sciences companies failed to complete their expected initial public offerings, as investors showed little interest in unprofitable companies. Complete Story » seekingalpha.com |
ESF: New skills for older workers - Video If you’re seeking a strong human interest story, then take a look at the European Social Fund. Far from being a set of dry statistics, the ESF is the framework for thousands of fascinating tales of individual human endeavour. feedproxy.google.com |
What Most Alkerme Investors Really Want M.E. Garza submits: By Patrick Crutcher Alkermes Inc. (NASDAQ:ALKS) has already received news from the FDA that they had approved their sNDA of Vivitrol for Prevention of Relapse to Opioid Dependence. This comes after unanimous support for Vivitrol during their FDA advisory panel back in mid-September. More importantly, there also appears to be excitement in the medical community for the new treatment option.Complete Story » seekingalpha.com |